Procter & Gamble Health cash flow

Latest FY25

Cash from operations: ₹228cr−3.3% on FY24
Capital spending: ₹21.7cr−48.8% on FY24
Free cash flow: ₹207cr+6.7% on FY24
Cash from financing: −₹418cr−₹98.5 cr in FY24

₹ crore except per share

Tap a line for its trend	FY27Jun 2026	FY26Jun 2025	FY25Jun 2024	FY24Jun 2023	FY23 and earlierAlpha Plus

Changes in working capital
Adjustments to reconcile profit — non-cash items					FY23 and earlierEvery year the company has filed comes with Alpha Plus.
	—	—	48.1	28.1
	—	—	0.7	0.8
	—	—	11.7	14.3
	—	—	0.7	0.6
	—	—	2.0	0.5
	—	—	−7.8	−2.7
	—	—	−2.1	0.0
	—	—	23.1	−32.4
	—	—	29.2	−32.9
	—	—	18.3	0.0
	—	—	0.0	−31.8
	—	—	−71.6	63.9
	—	—	−11.1	3.2
	—	—	−1.1	0.0
Cash from operating activities
	129	88.8	273	314
	—	—	40.2	11.5
	—	—	313	326
	—	—	85.2	89.7
	—	—	228	236
Cash from investing activities
	—	—	21.7	42.5
	—	—	0.1	4.7
	—	—	12.6	14.2
	—	—	2.1	2.1
	—	—	−6.9	−21.5
Cash from financing activities
	—	—	3.1	4.7
	—	—	415	93.8
	—	—	−418	−98.5
	—	—	−197	116
	—	—	−197	116
	—	—	239	435
Reference items
	99.6	90.3	306	324
	27.4%	26.7%	26.6%	26.4%
	—	—	207	194
	—	—	₹124.43	₹116.57
	—	—	1.14×	1.03×
	—	—	85.2	89.7

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

PGHL₹5,399.00

Procter & Gamble Health Limited

· Pharma & Health

₹ CrorePeersSANOFICONR SANOFI SENORES INNOVACAP MOREPENLAB IOLCP FDC ASTRAZENMcap ₹8,962 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY24 30/06/2023	FY25 30/06/2024	FY26 30/06/2025	FY27 30/06/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation	28.1	48.1	—	—
+ Finance Costs	0.8	0.7	—	—
+ Interest Income	14.3	11.7	—	—
+ Share-based Payments	0.6	0.7	—	—
+ Unrealised FX (Gain) / Loss	0.5	2.0	—	—
+ Other Non-cash Items	-2.7	-7.8	—	—
+ Other — Cash Effects are Investing / Financing	0.0	-2.1	—	—
Changes in Working Capital
+ Inventories	-32.4	23.1	—	—
+ Trade Receivables — Current	-32.9	29.2	—	—
+ Other Financial Assets — Current	0.0	18.3	—	—
+ Other Current Assets	-31.8	0.0	—	—
+ Trade Payables — Current	63.9	-71.6	—	—
+ Other Current Liabilities	3.2	-11.1	—	—
+ Provisions — Current	0.0	-1.1	—	—
Cash from Operating Activities
Profit Before Tax (per I/S)	314.2	273.3	88.8	129.1
+ Total Adjustments (incl. Working Capital)	11.5	40.2	—	—
Cash from Operations (pre-tax)	325.7	313.5	—	—
+ Income Taxes Paid	89.7	85.2	—	—
Cash from Operating Activities	236.0	228.3	—	—
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)	42.5	21.7	—	—
+ Disp of Fixed Assets	4.7	0.1	—	—
+ Interest Received — Investing	14.2	12.6	—	—
+ Other Inflows / (Outflows) — Investing	2.1	2.1	—	—
Cash from Investing Activities	-21.5	-6.9	—	—
Cash from Financing Activities
+ Payment of Lease Liabilities	4.7	3.1	—	—
+ Dividends Paid	93.8	415.0	—	—
Cash from Financing Activities	-98.5	-418.1	—	—
Net Changes in Cash (pre-FX)	116.0	-196.7	—	—
Net Changes in Cash	116.0	-196.7	—	—
Closing Cash	435.4	238.7	—	—
Reference Items
EBITDA	324.0	306.0	90.3	99.6
EBITDA Margin %	26.35	26.58	26.67	27.38
Free Cash Flow (CFO − Capex)	193.5	206.6	—	—
Free Cash Flow per Basic Share	116.57	124.43	—	—
Cash Flow to Net Income	1.03	1.14	—	—
Cash Paid for Taxes	89.7	85.2	—	—

As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY27 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.